South Anna-Maria, Babalonis Shanna L, Fanucchi Laura C, Lofwall Michelle R
Department of Internal Medicine, Division of Hospital Medicine, Addiction Consult and Education Service, College of Medicine, University of Kentucky, 800 Rose Street, Lexington, KY, 40536, USA.
Department of Behavioral Science, Center On Drug and Alcohol Research and Cannabis Center, College of Medicine, University of Kentucky, Lexington, KY, USA.
J Gen Intern Med. 2025 Jul 7. doi: 10.1007/s11606-025-09680-7.
Cannabis is increasingly legalized in more areas of the USA and marketed under the misnomer "medical cannabis." Yet, there are no official dosing guidelines or approved medical uses for plant cannabis by the Food and Drug Administration. Due to significant federal barriers, research on efficacy, safety, and adverse effects of cannabis is limited. Patients are interested in cannabis as potential treatment of medical issues and/or symptoms and clinicians should include a discussion of the risks of cannabis consumption. However, many risks are not yet known, and clinicians might be unaware of the emerging literature. This perspective summarizes the potential harms of cannabis, including the risk of cannabis use disorder, while providing a framework grounded in principles of medical ethics to educate patients on cannabis.
在美国,越来越多的地区将大麻合法化,并以“医用大麻”这一错误名称进行销售。然而,美国食品药品监督管理局并未制定关于植物大麻的官方给药指南,也未批准其任何医用用途。由于存在重大的联邦障碍,关于大麻的疗效、安全性和不良反应的研究有限。患者对大麻作为医疗问题和/或症状的潜在治疗方法感兴趣,临床医生应与患者讨论吸食大麻的风险。然而,许多风险尚不明确,临床医生可能也不了解最新的文献。本观点总结了大麻的潜在危害,包括大麻使用障碍的风险,同时提供了一个基于医学伦理原则的框架,用于对患者进行大麻相关知识的教育。